24 January 2019 Dorchester, UK: The founder of BioPortfolio Limited Peter Barfoot launched today a Private Memorandum outlining the opportunity to acquire the leading biotechnology, pharmaceutical and healthcare portal https://www.bioportfolio.com and associated research report store https://www.bioportfolio.co.uk.
"The acquisition of the BioPortfolio websites will provide the purchaser with a vehicle to develop a global presence in the life-science, biotechnology, pharmaceutical and healthcare research and investment space. BioPortfolio is a major internet provider in the delivery of corporate and industry news, peer reviewed research, clinical trials, market research and drug information" .
The new owners of the company will be in a strong position to readily exploit the breadth of the portals coverage and capitalize on the reputation that the website has achieved over the last twenty two years. The opportunity to control BioPortfolio delivers an “off-the-shelf” solution to accessing the global life-science internet audience.
The core benefits of acquiring BioPortfolio and associated websites are:
About BioPortfolio
BioPortfolio Limited was registered in February 1997 in England – Registration Number 03312883 and launched BioPortfolio.com (the “Site”) in the same month. The Site has continuously published life-science information to a global audience and has become one of leading life-science web portal specializing in the delivery of the most recent corporate news, research papers, clinical trials, market research and drug information.
The Site has a well-established and loyal readership, placing it on Alexa.com as the number one pharmaceutical and biotechnology directory. Readership has been built on the unique delivery of continuous, timely information, sourced from several hundred selected sources. Decision-makers in the life-science space, healthcare professionals and individuals interested in medical conditions and diseases can readily track new content as it is published.
The Site has been designed to be self-generating and updates automatically. The Site currently has over one million pages indexed in Google and an average monthly readership in excess of 100,000 users who view 155,000+ pages. Daily, several hundred pages are dynamically created via XML and RSS feeds from 700+ scheduled tasks that access, save and categorise the novel content into the news, research papers, clinical trials, reports, drugs and corporate databases.
To enhance the Company’s social media presence over 200 social media accounts, using the domain “bioporfol.io”, are continuously posting new content as it becomes available. This has resulted in 127,000+ social media followers on Twitter, Facebook, LinkedIn and Google+.
The Company’s revenue is derived from three core sources; the market report eCommerce store – www.bioportfolio.co.uk; advertising; and the publishing of press releases.
The Company and the Site have been structured to provide the new owner with an “off-the-shelf” solution with:
Contact:
To request a copy of the Private Memorandum please email your contact details, managerial position and specific interest in the business to Peter Barfoot, Managing Director, pdb@bioportfolio.com. Selected individuals/organizations will then be contacted.
This is not an offer to sell either the issued share capital or the trade of BioPortfolio Limited; it is not an investment and no liability is accepted for any inaccuracy in this press release.